Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
"This cup is the new testament in my blood, which is shed for you." (Luke 22:20). Most forms of Protestantism, especially those of a Methodist or Presbyterian lineage, teach that the wine is no more than a symbol of the blood of Christ, who is spiritually but not physically present. Lutheran theology teaches that the body and blood is present together "in, with, and under" the bread and wine of the Eucharistic feast.
=== Media === In literature, characters believed to exhibit signs of BPD include Catherine in Wuthering Heights (1847), Smerdyakov in The Brothers Karamazov (1880), and Harry Haller in Steppenwolf (1927). Films have also attempted to portray BPD, with characters in Margot at the Wedding (2007), Mr. Nobody (2009), Cracks (2009), Truth (2013), Wounded (2013), Welcome to Me (2014), and Tamasha (2015) all suggested to show traits of the disorder. The behavior of Theresa Dunn in Looking for Mr. Goodbar (1975) is consistent with BPD, as suggested by Robert O. Friedel. Films like Play Misty for Me (1971) and Girl, Interrupted (1999, based on the memoir of the same name) suggest emotional instability characteristic of BPD, while Single White Female (1992) highlights aspects such as identity disturbance and fear of abandonment. Clementine in Eternal Sunshine of the Spotless Mind (2004) is noted to show classic BPD behavior, and Carey Mulligan's portrayal in Shame (2011) is praised by psychiatrists for its accuracy regarding BPD characteristics. Television series like Crazy Ex-Girlfriend (2015) and the miniseries Maniac (2018) depict characters with BPD. Traits of BPD and narcissistic personality disorders are observed in characters like Cersei and Jaime Lannister from A Song of Ice and Fire (1996) and its TV adaptation Game of Thrones (2011). In The Sopranos (1999), Livia Soprano is diagnosed with BPD, and even the portrayal of Bruce Wayne/Batman in the show Titans (2018) is said to include aspects of the disorder.
285: 483-488, 2001) Molecular Pathomechanisms and New Trends in Drug Research (editor and co-author CRC Press Taylor and Frances Group, 2003) Drug discovery in the kinase inhibitory field using the Nested Chemical Library (TM) technology (co-author, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES 3: 543-551, 2005) Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death (co-author, CANCER RESEARCH 67:1602-1608, 2007) AXL is a potential target for therapeutic intervention in breast cancer progression (co-author, CANCER RESEARCH 68:1905-1915, 2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle (co-author, MOLECULAR CELL 31:438-448, 2008) Proteomics strategy for quantitative protein interaction profiling in cell extracts (co-author, NATURE METHODS 6: 741-744, 2009) Integrating molecular diagnostics into anticancer drug discovery (co-author NATURE REVIEWS DRUG DISCOVERY 9:(523-535, 2010) Development of a Cell Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate (co-author, BIOCONJUGATE CHEMISTRY 22:540-545,2011) Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance BIOCHEMICAL PHARMACOLOGY 84: 260-267, 2012 Developing FGFR4 inhibitors as potential anticancer agents via in silico design, supported by in vitro and cellbased (co-author CURRENT MEDICINAL CHEMISTRY 20:1203-1217, 2013
Sources: en.wikipedia.org
general studies of protein structure and properties (because it is available in large quantities). studies of serpin structure and function (the fact that ovalbumin does not inhibit proteases means that by comparing its structure with that of inhibitory serpins, the structural characteristics required for inhibition can be determined). proteomics (chicken egg ovalbumin is commonly used as a molecular weight marker for calibrating electrophoresis gels). immunology (commonly used to stimulate an allergic reaction in test subjects; e.g., established model allergen for airway hyper-responsiveness, AHR). (For in vivo and in vitro studies based on ovalbumin it is important that the endotoxin content is less than 1 EU/mg.)
== Development and evolution == The formation of rete pegs (often referred to as rete ridges in developmental biology) is driven by an evolutionary and molecular mechanism entirely distinct from the development of other skin appendages like hair follicles and sweat glands. In mammals, the evolutionary acquisition of epidermal rete ridges closely coincides with the loss of fur density. It is proposed that mammals replaced the genetic program for forming discrete microscopic appendages with a distinct program that creates this interconnected appendage network. During morphogenesis, the development of rete pegs requires significant signaling interactions between epidermal and dermal cells. Specifically, the broad epidermal activation of bone morphogenetic protein (BMP) signaling is required to organize the ridge networks around the underlying dermal pockets. While mature scar tissue in adults typically lacks rete pegs (making it more prone to shearing), recent studies in neonatal mammals, such as pigs, demonstrate that these epidermal structures can regenerate de novo during early wound healing.
==== Pre-workout ==== Another common supplement for bodybuilders is pre-workout. Pre-workout includes a mix of specific supplements aiming to boost energy and performance for a short period of time, often taken 30–60 minutes before a workout. Some of the most common supplements found in pre-workouts include L-arginine, L-citrulline, beetroot juice, caffeine, creatine, beta-alanine, and branched-chain amino acids (BCAAs). Pre-workout typically comes in the form of a powder, in a big container with a serving-sized scoop. Though it can be mixed it with any liquid, water is usually recommended for the best benefits. A common negative side effect associated with pre-workouts is impaired sleep. This is because the energy boost it provides can often last for hours on end, overall impairing sleep.
Sources: en.wikipedia.org
Small activating RNAs (saRNAs) are short double-stranded RNA molecules (typically 19–21 nucleotides in length) that induce transcriptional activation of target genes through a process known as RNA activation (RNAa). Unlike RNA interference (RNAi), which silences gene expression, saRNAs upregulate gene expression by targeting promoter regions of DNA and recruiting transcriptional machinery. The mechanism of RNAa involves the formation of an RNA-induced transcriptional activation (RITA) complex. This complex includes Argonaute proteins (particularly Ago2), RNA helicase A (RHA), and other transcriptional coactivators, which facilitate the activation of RNA polymerase II at the targeted promoter. This process is often associated with epigenetic changes, such as histone modifications, that promote active transcription. saRNAs have demonstrated potential in preclinical studies for treating diseases caused by insufficient gene expression, such as cancer and metabolic disorders. For example, saRNAs have been used to reactivate tumor suppressor genes in cancer cells, offering a promising therapeutic approach. Additionally, saRNAs are being explored for their ability to upregulate genes involved in metabolic regulation, neurodegenerative diseases, and other conditions. An example of an saRNA therapeutic in clinical development is MTL-CEBPA, which targets the CEBPA gene to treat liver cancer. This drug, developed by MiNA Therapeutics, has shown promise in early-phase clinical trials.
On 6 April 2019, it was announced at a press conference that Rieflin would take another break from King Crimson to attend to family matters; his place on keyboards for the 2019 50th anniversary tour was set to be taken by Theo Travis of Soft Machine, an occasional duo collaborator with Fripp. Although Travis joined the band for rehearsals, Fripp said on 2 May that the band had decided that it was no longer possible to have other musicians deputising for Rieflin and for this reason would "proceed as a Seven-Headed Beast" without Travis. Rieflin's parts were divided among Fripp, Stacey, Jakszyk, Collins, and Levin. On 11 June, King Crimson's entire discography was made available on streaming services, as part of the band's 50th anniversary celebration. On 24 March 2020, Rieflin died of cancer. In the same year, King Crimson collaborator Keith Tippett died after several years of illness on 14 June, and former bassist and singer Gordon Haskell died from lung cancer on 15 October. King Crimson toured North America and then Japan in 2021. Recordings from dates on the American leg of the tour were released as the "official bootleg" live album Music Is Our Friend: Live in Washington and Albany, featuring music from across the band's lifetime plus two new Tony Levin cadenzas.
Foreseeable use and misuse of the product Chemical, mechanical, and electrical hazards Vulnerable consumers, including children, elderly individuals, and persons with disabilities Where no harmonized standards exist, economic operators must use scientific and technical knowledge to ensure compliance.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.